Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010

被引：60

作者：

Ertl, Hildegund C. J. ^{[2
]}

Zaia, John ^{[4
]}

Rosenberg, Steven A. ^{[5
]}

June, Carl H. ^{[3
]}

Dotti, Gianpietro ^{[7
]}

Kahn, Jeffrey ^{[9
]}

Cooper, Laurence J. N. ^{[8
]}

Corrigan-Curay, Jacqueline ^{[6
]}

Strome, Scott E. ^{[1
]}

机构：

[1] Univ Maryland, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA

[2] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA

[3] Univ Penn, Philadelphia, PA 19104 USA

[4] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA USA

[5] NCI, Bethesda, MD 20892 USA

[6] NIH, Off Biotechnol Act, Off Director, Bethesda, MD 20892 USA

[7] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA

[8] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA

[9] Univ Minnesota, Ctr Bioeth, Minneapolis, MN USA

来源：

CANCER RESEARCH | 2011年 / 71卷 / 09期

关键词：

ADVERSE EVENT; PHASE-I; LYMPHOCYTES; GENE; CD28; COSTIMULATION; ACTIVATION; CD137; IMMUNOGLOBULIN; IMMUNOTHERAPY;

D O I：

10.1158/0008-5472.CAN-10-4035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

T cells that are genetically modified to express single-chain chimeric antigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials. Unfortunately, 2 recent deaths in cancer patients treated with CAR T cells have created some uncertainty on how to best mitigate patient risk, while continuing to advance this very promising therapeutic avenue. In order to address these concerns, the Recombinant DNA Advisory Committee (RAC) held a symposium, the objectives of which were to first review the reported treatment-associated toxicities and, second, to discuss methods for improving safety and efficacy. This report highlights the issues raised as part of this discussion, with a specific focus on protocols infusing CAR T cells. Because this was not a consensus conference, the opinions described should not be construed to represent those of any individual RAC member, the RAC as a body, conference participants, the National Institutes of Health, or the U. S. Food and Drug Administration. Cancer Res; 71(9); 3175-81. (C) 2011 AACR.

引用

页码：3175 / 3181

页数：7

共 30 条

[1] 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells [J].

Altvater, Bianca ;

Landmeier, Silke ;

Pscherer, Sibylle ;

Temme, Jaane ;

Schweer, Katharina ;

Kailayangiri, Sareetha ;

Campana, Dario ;

Juergens, Heribert ;

Pule, Martin ;

Rossig, Claudia .

CLINICAL CANCER RESEARCH, 2009, 15 (15) :4857-4866

[2] Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial [J].

Brentjens, Renier ;

Yeh, Raymond ;

Bernal, Yvette ;

Riviere, Isabelle ;

Sadelain, Michel .

MOLECULAR THERAPY, 2010, 18 (04) :666-668

[3]

BRENTJENS RJ, 2010, ANN M AM SOC GEN CEL

[4] Shaping up a lineage-lessons from B lymphopoesis [J].

Bryder, David ;

Sigvardsson, Mikael .

CURRENT OPINION IN IMMUNOLOGY, 2010, 22 (02) :148-153

[5] Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains [J].

Carpenito, Carmine ;

Milone, Michael C. ;

Hassan, Raffit ;

Simonet, Jacqueline C. ;

Lakhal, Mehdi ;

Suhoski, Megan M. ;

Varela-Rohena, Angel ;

Haines, Kathleen M. ;

Heitjan, Daniel F. ;

Albelda, Steven M. ;

Carroll, Richard G. ;

Riley, James L. ;

Pastan, Ira ;

June, Carl H. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (09) :3360-3365

[6] SPECIFIC ACTIVATION AND TARGETING OF CYTOTOXIC LYMPHOCYTES THROUGH CHIMERIC SINGLE CHAINS CONSISTING OF ANTIBODY-BINDING DOMAINS AND THE GAMMA-SUBUNIT OR ZETA-SUBUNIT OF THE IMMUNOGLOBULIN AND T-CELL RECEPTORS [J].

ESHHAR, Z ;

WAKS, T ;

GROSS, G ;

SCHINDLER, DG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :720-724

[7] Activation of resting human primary T cells with chimeric receptors:: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain [J].

Finney, HM ;

Akbar, AN ;

Lawson, ADG .

JOURNAL OF IMMUNOLOGY, 2004, 172 (01) :104-113

[8] Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation [J].

Friedmann-Morvinski, D ;

Bendavid, A ;

Waks, T ;

Schindler, D ;

Eshhar, Z .

BLOOD, 2005, 105 (08) :3087-3093

[9] EXPRESSION OF IMMUNOGLOBULIN-T-CELL RECEPTOR CHIMERIC MOLECULES AS FUNCTIONAL RECEPTORS WITH ANTIBODY-TYPE SPECIFICITY [J].

GROSS, G ;

WAKS, T ;

ESHHAR, Z .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (24) :10024-10028

[10] Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety [J].

Hoyos, V. ;

Savoldo, B. ;

Quintarelli, C. ;

Mahendravada, A. ;

Zhang, M. ;

Vera, J. ;

Heslop, H. E. ;

Rooney, C. M. ;

Brenner, M. K. ;

Dotti, G. .

LEUKEMIA, 2010, 24 (06) :1160-1170

← 1 2 3 →